Clinical intervention in the treatment of knee osteoarthritis with fire dragon pot

注册号:

Registration number:

ITMCTR2025000543

最近更新日期:

Date of Last Refreshed on:

2025-03-18

注册时间:

Date of Registration:

2025-03-18

注册号状态:

Registration Status:

预注册

Prospective registration

注册题目:

火龙罐治疗膝骨性关节炎临床干预

Public title:

Clinical intervention in the treatment of knee osteoarthritis with fire dragon pot

注册题目简写:

火龙罐治疗膝骨性关节炎

English Acronym:

Fire Dragon Cup for the Treatment of Knee Osteoarthritis

研究课题的正式科学名称:

火龙罐治疗膝骨性关节炎临床干预

Scientific title:

Clinical intervention in the treatment of knee osteoarthritis with fire dragon pot

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

李嘉玲

研究负责人:

张会凡

Applicant:

Jialing Li

Study leader:

Huifan Zhang

申请注册联系人电话:

Applicant telephone:

15989002013

研究负责人电话:

Study leader's telephone:

13724309697

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

976457954@qq.com

研究负责人电子邮件:

Study leader's E-mail:

nursingzhang@126.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

广州市番禺区大学城外环东路232号

研究负责人通讯地址:

深圳市罗湖区金塘街 40 号

Applicant address:

No. 232 East Ring Road University City Panyu District Guangzhou

Study leader's address:

No. 40 Jintang Street Luohu District Shenzhen

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

广东省广州市广州中医药大学

Applicant's institution:

Guangzhou University of Traditional Chinese Medicine Guangzhou Guangdong Province

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

KY2024002

伦理委员会批件附件:

Approved file of Ethical Committee:

View

批准本研究的伦理委员会名称:

深圳平乐骨伤科医院(深圳市坪山区中医院)医学伦理委员会

Name of the ethic committee:

Medical Ethics Committee of Shenzhen Pingle Orthopedic Hospital (Shenzhen Pingshan District Traditional Chinese Medicine Hospital)

伦理委员会批准日期:

Date of approved by ethic committee:

2024/3/7 0:00:00

伦理委员会联系人:

陈志新

Contact Name of the ethic committee:

Zhixin Chen

伦理委员会联系地址:

深圳平乐骨伤科医院(深圳市坪山区中医院)

Contact Address of the ethic committee:

Shenzhen Pingle Orthopedics Hospital (Shenzhen Pingshan District Hospital of Traditional Chinese Medicine)

伦理委员会联系人电话:

Contact phone of the ethic committee:

0755-23379119

伦理委员会联系人邮箱:

Contact email of the ethic committee:

2852365658@qq.com

研究实施负责(组长)单位:

深圳平乐骨伤科医院(深圳市坪山区中医院)

Primary sponsor:

Shenzhen Pingle Orthopedics Hospital (Shenzhen Pingshan District Traditional Chinese Medicine Hospital

研究实施负责(组长)单位地址:

深圳市罗湖区金塘街 40 号

Primary sponsor's address:

No. 40 Jintang Street Luohu District Shenzhen

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

广东

市(区县):

广州

Country:

China

Province:

GuangDong

City:

GuangZhou

单位(医院):

广东省中医药局

具体地址:

广东省广州市越秀区东风中路483号粤财大厦24层

Institution
hospital:

Guangdong Provincial Bureau of Traditional Chinese Medicine

Address:

Floor 24 Yuecai Building No. 483 Dongfeng Middle Road Yuexiu District Guangzhou City Guangdong Province

经费或物资来源:

广东省中医药局科研课题

Source(s) of funding:

Scientific research project of Guangdong Provincial Bureau of Traditional Chinese Medicine

研究疾病:

膝骨性关节炎

研究疾病代码:

Target disease:

knee osteoarthritis

Target disease code:

研究类型:

Study type:

干预性研究

Interventional study

研究设计:

Study design:

随机平行对照

randomized controlled trial(parallel group design)

研究所处阶段:

Study phase:

治疗新技术临床试验

New Treatment Measure Clinical Study

研究目的:

验证火龙罐治疗膝关节骨性关节炎的疗效

Objectives of Study:

Verify the efficacy of fire dragon pot in treating knee osteoarthritis

药物成份或治疗方案详述:

Description for medicine or protocol of treatment in detail:

纳入标准:

①符合诊断标准;②年龄18~70岁;③符合疾病分期中的早中期(按K-L的放射学标准),将骨关节炎按严重程度分为0~Ⅳ级,本研究只纳入K-L分级为0~Ⅱ级者;④自愿加入本研究并签署知情同意书。

Inclusion criteria

① Meet the diagnostic criteria; ② Aged 18 to 70 years old; ③ Meet the early and middle stages of the disease staging (according to K-L radiological standards [10] osteoarthritis is divided into grades 0 to IV according to severity this study only included K-L Those classified as level 0 to level II; ④ Voluntarily join this study and sign the informed consent form.

排除标准:

①外伤者;②K-L分级Ⅲ~Ⅳ者;③痛风或类风湿等其他类型关节炎;④合并严重肝肾功能不全、严重心脑血管疾病或肿瘤、结核等其他严重内科疾病者;⑤对本研究药物(塞来昔布)过敏者;⑥沟通障碍或无法耐受火龙罐者;⑦哺乳、怀孕妇女

Exclusion criteria:

① Those with trauma; ② Those with K-L grades III to IV; ③ Other types of arthritis such as gout or rheumatoid; ④ Those combined with severe liver and kidney insufficiency severe cardiovascular and cerebrovascular diseases or other serious medical diseases such as tumors and tuberculosis; ⑤ Those with this disease Those who are allergic to the study drug (celecoxib); ⑥ Those with communication difficulties or unable to tolerate fire dragon pot; ⑧ Lactating and pregnant women.

研究实施时间:

Study execute time:

From 2024-09-01

To      2025-12-31

征募观察对象时间:

Recruiting time:

From 2025-04-01

To      2025-10-31

干预措施:

Interventions:

组别:

观察组

样本量:

40

Group:

Observation group

Sample size:

干预措施:

火龙罐+中西医整体护理

干预措施代码:

Intervention:

Fire Dragon Jar + Traditional Chinese and Western Medicine Holistic Care

Intervention code:

组别:

对照组

样本量:

40

Group:

Control group

Sample size:

干预措施:

塞来昔布胶囊+中西医整体护理

干预措施代码:

Intervention:

Celecoxib Capsules + Traditional Chinese and Western Medicine Holistic Care

Intervention code:

样本总量 Total sample size : 80

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

广东

市(区县):

深圳

Country:

China

Province:

Guangdong

City:

Shenzhen

单位(医院):

深圳平乐骨伤科医院(深圳市坪山区中医院)

单位级别:

三甲

Institution/hospital:

Shenzhen Pingle Orthopedics Hospital (Shenzhen Pingshan District Traditional Chinese Medicine Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

中医症状及体征评分

指标类型:

次要指标

Outcome:

Traditional Chinese Medicine symptom and sign score

Type:

Secondary indicator

测量时间点:

治疗前、治疗后、治疗后2周随访

测量方法:

Measure time point of outcome:

Before treatment after treatment and follow-up 2 weeks after treatment

Measure method:

指标中文名:

疼痛视觉模拟评分

指标类型:

次要指标

Outcome:

Visual Analogue Scale

Type:

Secondary indicator

测量时间点:

治疗前、治疗后、治疗后2周随访

测量方法:

Measure time point of outcome:

Before treatment after treatment and follow-up 2 weeks after treatment

Measure method:

指标中文名:

不良事件发生率

指标类型:

次要指标

Outcome:

Adverse event rate

Type:

Secondary indicator

测量时间点:

研究过程中及研究结束时

测量方法:

Measure time point of outcome:

During and after the study

Measure method:

指标中文名:

西安大略与麦克马斯特大学骨关节炎指数评分

指标类型:

主要指标

Outcome:

Western Ontario and McMaster Universities Osteoarthritis Index(WOMAC)

Type:

Primary indicator

测量时间点:

治疗前、治疗后、治疗后2周随访

测量方法:

Measure time point of outcome:

Before treatment after treatment and follow-up 2 weeks after treatment

Measure method:

指标中文名:

奎森功能障碍指数

指标类型:

次要指标

Outcome:

Lequesne Scale

Type:

Secondary indicator

测量时间点:

治疗前、治疗后、治疗后2周随访

测量方法:

Measure time point of outcome:

Before treatment after treatment and follow-up 2 weeks after treatment

Measure method:

指标中文名:

美国特种外科医院膝关节评分

指标类型:

次要指标

Outcome:

Hospital for Special Surgery(HSS)

Type:

Secondary indicator

测量时间点:

治疗前、治疗后、治疗后2周随访

测量方法:

Measure time point of outcome:

Before treatment after treatment and follow-up 2 weeks after treatment

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

None

Tissue:

人体标本去向

其它

说明

Fate of sample 

Others

Note:

征募研究对象情况:

尚未开始

Not yet recruiting

年龄范围:

最小 18
Min age years
最大 70
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男女均可

Both

随机方法(请说明由何人用什么方法产生随机序列):

本研究采用简单随机的方法,由第三方机构产生随机列表,并用信封隐匿。

Randomization Procedure (please state who generates the random number sequence and by what method):

This study adopted a simple randomization method with a random list generated by a third-party organization and concealed in an envelope.

盲法:

Blinding:

None

是否共享原始数据:

IPD sharing:

No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

NA

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

NA

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

CRF

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

CRF

数据管理委员会:

Data Managemen Committee:

Yes

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

ITMCTR BJ-ICP:07032215-5 Tip: IE8 is recommended Use the system with widescreen display resolution above